CA2865351C - Thiadiazolidinediones as gsk-3 inhibitors - Google Patents

Thiadiazolidinediones as gsk-3 inhibitors Download PDF

Info

Publication number
CA2865351C
CA2865351C CA2865351A CA2865351A CA2865351C CA 2865351 C CA2865351 C CA 2865351C CA 2865351 A CA2865351 A CA 2865351A CA 2865351 A CA2865351 A CA 2865351A CA 2865351 C CA2865351 C CA 2865351C
Authority
CA
Canada
Prior art keywords
compound
formula
solvate
disease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2865351A
Other languages
English (en)
French (fr)
Other versions
CA2865351A1 (en
Inventor
Miguel Medina Padilla
Juan Manuel Dominguez Correa
Javier DE CRISTOBAL BLANCO
Ana Fuertes Huerta
Jorge Sanchez-Quesada
Javier Lopez Ogalla
Susana Herrero Santos
Maria Angeles Perez De La Cruz Moreno
Olga Martinez Montero
Beatriz Rodriguez Salguero
Francisco Palomo Nicolau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASD Therapeutics Partners LLC
Original Assignee
ASD Therapeutics Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASD Therapeutics Partners LLC filed Critical ASD Therapeutics Partners LLC
Publication of CA2865351A1 publication Critical patent/CA2865351A1/en
Application granted granted Critical
Publication of CA2865351C publication Critical patent/CA2865351C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2865351A 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors Active CA2865351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382066 2012-02-24
EP12382066.4 2012-02-24
PCT/EP2013/053554 WO2013124413A1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
CA2865351A1 CA2865351A1 (en) 2013-08-29
CA2865351C true CA2865351C (en) 2019-08-20

Family

ID=47747639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865351A Active CA2865351C (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Country Status (18)

Country Link
US (2) US9371299B2 (enExample)
EP (1) EP2838888B1 (enExample)
JP (2) JP6073377B2 (enExample)
AU (2) AU2013224041B2 (enExample)
CA (1) CA2865351C (enExample)
CY (1) CY1119231T1 (enExample)
DK (1) DK2838888T3 (enExample)
ES (1) ES2632428T3 (enExample)
HR (1) HRP20170964T1 (enExample)
HU (1) HUE035089T2 (enExample)
IN (1) IN2014DN07885A (enExample)
LT (1) LT2838888T (enExample)
NZ (1) NZ630615A (enExample)
PL (1) PL2838888T3 (enExample)
PT (1) PT2838888T (enExample)
SI (1) SI2838888T1 (enExample)
WO (1) WO2013124413A1 (enExample)
ZA (1) ZA201406225B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124413A1 (en) 2012-02-24 2013-08-29 Noscira, S.A. Thiadiazolidinediones as gsk-3 inhibitors
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
KR102567244B1 (ko) * 2014-06-12 2023-08-16 세다르스-신나이 메디칼 센터 암을 치료하는 조성물 및 방법
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
US12042949B2 (en) * 2018-10-16 2024-07-23 Italia Technology Alliance S.R.L. Winding machine with an evaluation system of the web material being processed and method
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US12150936B2 (en) * 2021-02-11 2024-11-26 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408747C (en) * 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
WO2013124413A1 (en) 2012-02-24 2013-08-29 Noscira, S.A. Thiadiazolidinediones as gsk-3 inhibitors

Also Published As

Publication number Publication date
AU2017248556B2 (en) 2018-08-09
DK2838888T3 (en) 2017-07-17
JP6073377B2 (ja) 2017-02-01
AU2017248556A1 (en) 2017-11-09
US20160257660A1 (en) 2016-09-08
ES2632428T3 (es) 2017-09-13
PL2838888T3 (pl) 2017-12-29
NZ630615A (en) 2015-09-25
ZA201406225B (en) 2016-05-25
JP6518270B2 (ja) 2019-05-22
US9469618B2 (en) 2016-10-18
PT2838888T (pt) 2017-07-18
AU2013224041A1 (en) 2014-09-25
WO2013124413A1 (en) 2013-08-29
CA2865351A1 (en) 2013-08-29
HRP20170964T1 (hr) 2017-10-06
SI2838888T1 (sl) 2017-09-29
EP2838888A1 (en) 2015-02-25
JP2015508092A (ja) 2015-03-16
US9371299B2 (en) 2016-06-21
CY1119231T1 (el) 2018-02-14
EP2838888B1 (en) 2017-04-12
AU2013224041B2 (en) 2017-08-24
US20150038538A1 (en) 2015-02-05
LT2838888T (lt) 2017-08-10
IN2014DN07885A (enExample) 2015-04-24
HK1207366A1 (en) 2016-01-29
HUE035089T2 (hu) 2018-05-02
JP2017081974A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
AU2017248556B2 (en) Thiadiazolidinediones as gsk-3 inhibitors
TWI352084B (en) Gsk-3 inhibitors
AU2007245625B2 (en) N- ( 2-thiazolyl) -amide derivatives as GSK-3 inhibitors
KR101471999B1 (ko) Ｇｓｋ-3 저해제
US20050054698A1 (en) 4-(4Methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3)
JP2016525104A (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
HK1207366B (en) Thiadiazolidinediones as gsk-3 inhibitors
WO2013149976A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
EP2527322A1 (en) Carbamyl alkylphenyl disulfide derivatives and their therapeutic uses
EP2527323A1 (en) Urea carbonyl disulfide derivatives and their therapeutic uses
WO2013167635A1 (en) Therapeutic use of indole-dihydro-imidazole derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170814

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250214

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260216